Market Overview

Benzinga's Top Pre-Market Losers

Related GILD
Gilead's Zydelig® Combined with Bendamustine and Rituximab Shows Superior Efficacy to Bendamustine/Rituximab in Phase 3 Study of Patients with Relapsed Chronic Lymphocytic Leukemia
Multiple Scientific Presentations at The Liver Meeting 2015 Further Highlight the Utility of Sofosbuvir-Based Hepatitis C Therapies
Weekly Wrap-Up Market Forecast Sector Watch SPX Nasdaq BTK FAS XLE IGV CELG BIIB AGN PFE CRM AMGN GILD SPLK GS WFC JPM (Marketfy Insights)
Related CROX
Crocs Downgraded At Piper Jaffray On 'Dead Money' Thesis
Morning Market Losers

Gilead Sciences (NASDAQ: GILD) dipped 2.40% to $58.66 in the pre-market session. Gilead Sciences shares have jumped 124.40% over the past 52 weeks, while the S&P 500 index has gained 25.09% in the same period.

Crocs (NASDAQ: CROX) shares fell 2.09% to $16.40 in the pre-market trading after Wedbush downgraded the stock from “outperform” to “neutral.”

Broadcom (NASDAQ: BRCM) shares dropped 1.45% to $33.20 in pre-market trading. Broadcom's trailing-twelve-month ROA is 4.58%.

Honeywell International (NYSE: HON) dipped 0.49% to $83.16 in the pre-market session after Nomura downgraded the stock from “buy” to “neutral.”

Posted-In: Top Pre-Market LosersNews Movers & Shakers Pre-Market Outlook Markets


Related Articles (BRCM + CROX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters